Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 25Unknown 11Recruiting 5Terminated 3Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Colonic Neoplasms 2Rectal Neoplasms 1Pancreatic Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Fluorouracil 12Oxaliplatin 11Leucovorin 10Irinotecan 7Capecitabine 7regorafenib 4Radiotherapy 4Bevacizumab 4aflibercept 2Reverse Transcriptase Polymerase Chain Reaction 2Radiation 2Neoadjuvant Therapy 2Biopsy 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1sulindac sulfone 1sargramostim 1pembrolizumab 1lonafarnib 1irofulven 1infigratinib 1dehydroftorafur 1balstilimab 1XELOX 1Trifluridine 1Trastuzumab 1Transplantation 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Rectal Neoplasms × Folfox protocol × Clear all
NCT01270438 2017-04-04

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡